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 Abstract 
 Total quality in laboratory medicine should be defined 
as the guarantee that each activity throughout the total 
testing process is correctly performed, providing  valuable 
medical decision-making and effective patient care. In the 
past decades, a 10-fold reduction in the analytical error 
rate has been achieved thanks to improvements in both 
reliability and standardization of  analytical techniques, 
reagents, and instrumentation. Notable advances in infor-
mation technology, quality control and quality assurance 
methods have also assured a valuable contribution for 
reducing diagnostic errors. Nevertheless, several lines of 
evidence still suggest that most errors in laboratory diag-
nostics fall outside the analytical phase, and the pre- and 
postanalytical steps have been found to be much more vul-
nerable. This collective paper, which is the logical contin-
uum of the former already published in this journal 2 years 
ago, provides additional contribution to risk management 
in the preanalytical phase and is a synopsis of the lectures 
of the 2nd European Federation of Clinical Chemistry and 
Laboratory Medicine (EFLM)-Becton Dickinson (BD) Euro-
pean Conference on Preanalytical Phase meeting entitled 
 “ Preanalytical quality improvement: in quality we trust ” 
(Zagreb, Croatia, 1 – 2 March 2013). The leading topics that 
will be discussed include quality indicators for preanalyti-
cal phase, phlebotomy practices for collection of blood gas 
analysis and pediatric samples, lipemia and blood collec-
tion tube interferences, preanalytical requirements of uri-
nalysis, molecular biology hemostasis and platelet testing, 
as well as indications on best practices for safe blood col-
lection. Auditing of the preanalytical phase by ISO asses-
sors and external quality assessment for preanalytical 
phase are also discussed. 
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 Introduction 
 With the dark shadows of one of the biggest financial crises 
ever since the second world war still spreading throughout 
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most industrialized and emerging countries, policy-makers 
and national governments are urgently realizing spending 
reviews and other economic frameworks to prevent unnec-
essary waists and limit the downward spiral of internal 
economies. In several countries the  dramatic consequences 
of this awkward scenario have also inflated and eroded 
resources of national healthcare systems, which are now 
struggling to maintain unaltered the access to care, contain 
spiraling healthcare costs or maintain sustainable gains in 
coverage. It may seem paradoxical to most, but in several 
countries the substantial reduction of healthcare funding 
realized within pressing health care reforms not only has 
strongly infected anticompetitive practices of healthcare 
organizations, but also those healthcare areas that are tra-
ditionally virtuous for their highly accountable and easily 
monitored budgets, thus including in vitro diagnostic 
testing  [1, 2] . As a consequence, clinical laboratories are 
now squeezed between a rock and a hard place, where the 
need to preserve a high degree of quality is weighted against 
a lower economic support by central governments. 
 There is a common misconception about quality of 
care,  wherein healthcare is frequently assimilated with 
other  “ industries ” as a product or service that helps some-
body and enjoys a good and sustainable market. The quality 
of care is, however, much more than a simple and academic 
notion, since it has now became crucial for patient well-
being and for economical survival of the healthcare itself 
 [3] . More credibly, quality of care consists of  “ … the degree 
to which health services for individuals and populations 
increase the likelihood of desired health outcomes, are 
consistent with current professional knowledge, and meet 
the expectations of healthcare users ”  [4] . The field of labo-
ratory diagnostics has been a forerunner in pursuing total 
quality, inasmuch as safeness and excellence throughout 
the total testing process have been firmly established more 
than a century ago  [5] , and continually reaffirmed with 
publication of original studies, case reports, editorials, crit-
ical reviews and even meta-analyses, that have swollen the 
pages of this journal since its birth, 50 years ago  [6] . 
 Quality in laboratory medicine should be defined as the 
guarantee that each single step throughout the total testing 
process is correctly performed, thus assuring valuable 
medical decision-making and effective patient care  [7] . In the 
past decades, a 10-fold reduction in the analytical error rate 
has been achieved thanks to improvements in the reliability 
and standardization of analytical techniques, reagents, and 
instrumentation  [8] . Notable advances in information tech-
nology, quality control and quality assurance methods have 
also assured a valuable contribution for reducing uncertain-
ties, so that the overall rate of laboratory errors is now estab-
lished at nearly 4.6 sigma, improved by nearly 0.15 sigma (or 
 otherwise 1600 ppm) in the past 10 years and, much lower 
than the chance of losing your luggage in the airport (i.e., 4.0 
sigma) or suffering from a diagnostic error in radiology (i.e., 
3.24 sigma) (Figure  1 )  [9] . However, whilst current quality 
indicators in laboratory medicine still tend to focus on the 
performance and efficiency of analytical processes, several 
lines of evidence suggest that most errors in the total testing 
process actually fall outside the analytical phase, and the 
pre- and postanalytical steps have been found to be much 
more vulnerable  [10 – 13] . The minor attention paid to extra 
laboratory factors is thus in stark contrast with the body of 
evidence pointing to the multitude of errors that continue to 
occur in the preanalytical phase. This article, which is the 
logical continuum of the former already published in this 
journal 2 years ago, provides additional contribution to risk 
management in the preanalytical phase and is a synopsis 
of the lectures of the 2nd European Federation of Clinical 
Chemistry and Laboratory Medicine (EFLM)-Becton Dick-
inson (BD) European Conference on Preanalytical Phase 
meeting entitled  “ Preanalytical quality improvement: in 
quality we trust ” (Zagreb, 1 – 2 March 2013) ( http://www.pre-
analytical-phase.org/node/1 ). The leading topics that will 
be discussed include quality indicators for the preanalytical 
phase, insights about phlebotomy practices including col-
lection of suitable samples for blood gas analysis and pedi-
atric testing, lipemia and blood collection tube interferences 
on clinical chemistry assays, preanalytical requirements 
of urinalysis, molecular biology hemostasis and platelet 
testing, as well as indications on how safe sharps and other 
best practices should be implemented and monitored. A 
general overview about auditing of the preanalytical phase 
by International Organization for Standardization (ISO) 
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 Figure 1   Six sigma metrics of laboratory errors. 
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assessors and external quality assessment for preanalytical 
phase will also be provided. 
 The EFLM working group on the 
 preanalytical phase 
 It is a common perception that excellence in laboratory 
diagnostic is often perceived as a synonymous of analytical 
quality. The newly established EFLM working group WG-
Preanalytical phase is intended to fill a gap in the current 
international scientific activity about total quality in labo-
ratory diagnostics. With already existent WGs, either sup-
ported by the International Federation of Clinical Chemistry 
and Laboratory Medicine (IFCC) or EFLM, being focused on 
the analytical quality or on quality indicators (see below), 
the aims of the EFLM working group WG-Preanalytical 
phase are to assess excellence in current preanalytical prac-
tices, identify some of the most critical elements and make 
recommendations to reduce the impact of the preanalytical 
phase in laboratory medicine for the most critical segments 
of this framework  [12] . Several educational and scientific 
activities are already ongoing. An international, educational 
meeting supported by the EFLM has already been success-
fully organized in Parma, Italy in 2011, while the second 
edition will take place in Zagreb, Croatia in 2013. The focus 
of both conferences is the management of quality of the pre-
analytical laboratory practices, by designing attractive sci-
entific programs with interactive discussions and e-voting 
sessions to enable the exchange of ideas and knowledge 
related to some most common issues and everyday prob-
lems. Another important initiative is a European survey 
concerning phlebotomy practices, containing 16 questions, 
which will help identify by whom phlebotomy is done and 
what level of education is required for this specific task. It is 
our intendment that the outcome of this survey will contrib-
ute to define reference (best) practices in this field, as well 
as issue recommendations or guidelines about this essential 
but often neglected laboratory practice. 
 Quality indicators in the 
 preanalytical phase 
 According to the approach of the Institute of Medicine (IOM) 
to quality in healthcare, the identification of reliable quality 
indicators (QIs) is a crucial step in enabling users to quan-
tify the quality of a selected aspect of care, by comparing 
it against a defined criterion. A quality indicator is thus 
 “ an objective measure that potentially evaluates all critical 
care domains as defined by the IOM (patient safety, effec-
tiveness, equity, patient-centeredness, timeliness and effi-
ciency), that is based on evidence associated with those 
domains, and can be implemented in a consistent and com-
parable manner across settings and over time ” . Therefore, 
when assessing the quality of laboratory services by QIs, it 
is important to ensure systematic and consistent data col-
lection and analysis by using a comprehensive set of indica-
tors that address all stages of the total testing process, and 
focus on the areas with an important impact on patient care 
and health outcomes. The need to harmonize proposed QIs 
has also been emphasized, as several projects have been 
launched in different countries including Spain, Brazil, 
Australia, Croatia, China and the UK, but with the use of dif-
ferent approaches and quality measures  [14] . In 2008, the 
IFCC launched a working group named  “ Laboratory errors 
and patient safety ” , its primary goal being the identification 
and evaluation of reliable QIs and related quality specifica-
tions for addressing all the stages of the total testing process 
 [15, 16] . The prerequisites for selected QIs were: 1) relevance 
and applicability to a wide range of  clinical laboratories at 
an international level; 2) scientific  soundness, with a focus 
on areas of great importance for quality in laboratory medi-
cine; 3) feasibility, both regarding the data availability and 
the definition of thresholds for acceptable performance; and 
4) timeliness and possible use as a measure or surrogate of 
laboratory improvement. Up to 56 QIs have been identi-
fied, 34 of which are in the preanalytical, seven are in the 
intra- and 15 are in the postanalytical phase. The aims of, 
and steps undertaken in the IFCC-WG program have already 
been described and preliminary results presented for better 
addressing future steps of the project particularly as regards 
pre- and postanalytical indicators. 
 Consequences of blood collection 
errors 
 The value of laboratory responsibilities to patient- 
centered care and safety is becoming increasingly appar-
ent, especially as new sophisticated laboratory testing 
becomes available, particularly complex genetic tests. The 
preanalytical phase, including each step in venipuncture 
is exceptionally crucial because most of the preanalyti-
cal variables and factors can be controlled by the health-
care professional collecting biological samples  [17 – 19] . 
As every step in the formulation of test results must be 
of superlative quality, major focus should be redirected 
toward quality assurance aspects of patient preparation, 
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safety, specimen collection and specimen transportation 
to avoid preanalytical errors in laboratory testing. The var-
iables found when dealing with patients and laboratory 
situations require professional problem-solving skills. 
 Since phlebotomy is the most commonly performed 
medical procedure worldwide, the administrative direc-
tors, pathologists, supervisors and phlebotomists need to 
take the time to routinely review the high-risk procedures 
that can lead to adverse problems and incidents affect-
ing patient safety  [20] . Based upon the generated list, the 
controllable (preventable) vs. non-controllable variables 
in preanalytical procedures need to be assessed as to the 
ones that have impact on preanalytical errors and patient 
safety. Also, inviting input from the patients and their 
families is becoming a communicative source for improv-
ing the safety and quality of the laboratory testing. 
 Some major physiological variables that are controlla-
ble and can affect the results of laboratory analysis include 
diet, physical exercise, circadian rhythm, posture or pro-
longed bed rest, travel and other lifestyle factors. Health-
care professionals involved in blood collection must be 
educated to become cognizant of the communication skills 
that should be used prior to blood collection to oversee the 
controllable variables, including fainting and patients who 
have had a mastectomy  [21] . The healthcare professional 
must be proactive in asking the patient who is to have his/
her blood collected questions regarding these medical con-
ditions and have the knowledge base to move forward in a 
safe and risk reduced blood collection procedure. 
 Patient safety related to patient identification is an 
ongoing controllable challenge in all types of blood collec-
tion procedures. Also, using the correct blood collection 
equipment in venipuncture and skin puncture is an ongoing 
preanalytical challenge and requires continuous educa-
tional updates as equipment is changed in the healthcare 
institutions. Controllable variables, including tourniquet 
and fist pressure, are constant issues that must be overseen 
in appropriate blood collection. Hemolyzed blood is the 
most common reason for rejecting specimens in the labora-
tory and, therefore, in-depth knowledge on how to properly 
enter the vein with the correct blood collection equipment 
to avoid hemolysis in the collected specimens is a must for 
the phlebotomist. Improper blood  collection tubes lead to 
numerous preanalytical errors and can adversely affect 
patient laboratory results and safety. Risk reduction in using 
blood collection equipment with congruent pieces is an eve-
ryday challenge for healthcare institutions in attempting to 
maintain their staff with the latest knowledge base on these 
issues. These are examples of the many controllable vari-
ables that can be overseen to assist in better blood analyte 
results, less patient errors, and improved patient safety. 
 Blood gas collection 
 Arterial blood gas (ABG), which typically entails the 
puncturing of a superficial artery for drawing arterial 
blood by means of a thin needle and small syringe, is 
mainly performed for gathering useful information 
about blood gases. It is thereby mainly aimed at meas-
uring the arterial oxygen tension (PaO 2 ), carbon dioxide 
tension (PaCO 2 ), and pH, along with other useful param-
eters such as oxyhemoglobin saturation (SaO 2 ), partial 
pressure of carbon dioxide (CO 2 ), bicarbonate and blood 
lactate. As for other in vitro diagnostic tests, ABG may 
be vulnerable to errors throughout the total testing 
process, especially in the preanalytical phase  [10 – 12] . 
The peculiar biological matrix of this test that is the 
use of whole heparinized blood, makes however rather 
challenging the identification of some preanalytical 
errors, especially those attributable to interference from 
spurious hemolysis, lipemia and turbidity. Neverthe-
less, recent studies suggest that the chance of process-
ing unsuitable blood may be noting but meaningless in 
this setting. In an investigation of all samples referred 
for ABG in the laboratory of the large Academic Hos-
pital of Parma, which were systematically centrifuged 
after testing had been completed, Lippi et  al. found a 
rate of visible hemolysis of 1.2 %  [22] . In a further study, 
Salvagno et  al. assessed the serum indices after cen-
trifugation of all routine and stat samples referred for 
ABG analysis to the clinical laboratory of the Academic 
Hospital of Verona over a 2-month period  [23] . Interest-
ingly, 28 % of these displayed at least one serum index 
exceeding the cut-off (27 % from the emergency depart-
ment and 29 % from clinical wards). More specifically, 
4 % of samples displayed a hemolysis index over 60, 
11 % a lipemic index over 30, and 13 % an icteric index 
over 2. The rate of hemolyzed specimens from the emer-
gency department was exactly double that of clinical 
wards (6 % vs. 3 % ), whereas the rate of other types of 
unsuitable specimens was globally comparable (i.e., 9 % 
vs. 12 % , and 12 % vs. 14 % for lipemic and icteric speci-
mens, respectively). This data attest that preanalytical 
non-conformance may be frequent in ABG analysis, at 
rates comparable and even higher than those recorded 
for other in vitro diagnostic tests. Whenever highly devi-
ating test results are produced or when there are reason-
able doubts about the quality of the ABG specimen, it 
may henceforth be advisable to set a rapid centrifuga-
tion of the sample followed by assessment of the serum 
indices on the plasma. This can be regarded as a reliable 
approach to identify potentially unsuitable samples and 
prevent unreliable test results from being released. 
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 Pediatric blood collection 
 Children should not be considered as little adults or minia-
tures, and their unique physical and mental development, 
growth, nutrition and diseases should not be overlooked 
in all medical fields. Pediatric care is provided in various 
environments, including offices of primary care physi-
cians, pediatricians, general practitioners, public health 
clinics, acute care facilities, general hospitals, children ’ s 
hospitals, as well as academic medical centers. Labora-
tory diagnostics in outpatient settings differ from in-hos-
pital testing. However, laboratory results are affected in 
all pediatric settings, and predominantly by preanalyti-
cal variables. Patient age can hence be considered one of 
the most important preanalytical variables  [24] . Each step 
of blood collection in selected pediatric age group such 
as the preparation of the child before the procedure with 
or without the help of parents, preparation of the blood 
 collection site, equipment for specimen collection, the 
specimen collection itself, and handling and storage of 
the specimen is thereby unique. 
 The performance of venipuncture in both infants and 
children requires special training and skill, particularly for 
sites such as scalp and jugular veins and umbilical artery 
catheters. In infants,  < 5 % of the total blood volume should 
be removed in a single draw, but several blood draws per 
day may be requested in acutely ill inpatients  [21, 25] . The 
most suitable mean to reduce the risk of iatrogenic anemia 
and transfusion is obviously the reduction of sample 
volume. Skin puncture procedure in laboratory testing is 
traditionally more frequent in children than in adults, the 
heel and fingertip being the more common sites. The Uni-
versity Children ’ s Hospital in Bratislava offers a wide range 
of inpatient and outpatient services. The hospital is a 
397-bed pediatric facility, consisting of 11 clinics and eight 
departments, with centers for cardiology, pediatric dialy-
sis, bone marrow and liver transplantation, and inherited 
metabolic diseases. The study performed in the hospital 
hematology laboratory contributed to implementation 
of an innovative blood collection tube Becton Dickinson 
(BD) Microtainer  ®  MAP Microtube for Automated Process 
(MAP) which is intended for the collection, anticoagula-
tion, transport and storage of skin puncture specimen 
for routine hematology testing on automated hematology 
systems, and is targeted for pediatric, geriatric, oncology, 
neonatal intensive care unit patients, as well as for the 
general population in selected circumstances  [26] . 
 The current procedures for blood collection should 
be safe for patients during various periods of infancy, 
childhood and adolescence, and at the same time it 
should provide quality specimen and sufficient volume 
for laboratory testing. On one side detailed guidelines, 
special equipment and devices, qualified and experi-
enced health workers are needed, on the other manufac-
turing and implementation in the laboratory testing prac-
tice of new types of pediatric-sized tubes and advanced 
automated laboratory instruments with minimized speci-
men volumes and dead volume lower than 50  μ L may be 
required for achieving further improvements. 
 Blood collection tube interference 
on clinical chemistry assays 
 Substantial changes in the tubes that are used for collec-
tion of blood for most laboratory tests have occurred over 
the past two decades. Two of the most popular changes 
include: 1) a polymer gel in the bottom of the evacuated 
blood collection tubes; and 2) replacement of plastic for 
glass as the primary tube component. These changes pro-
vided a number of practical operational advantages, such 
as reduced centrifugation time, ability to use primary 
collection tubes for testing, increased sample stability in 
collection tubes, decreased breakage hazard, decreased 
weight, and suitability for disposal by incineration  [27] . 
Blood collection tubes are, however, much more complex 
devices than is commonly appreciated by most laboratory 
professionals. Commercial tubes have multiple compo-
nents that contribute to the optimal separation of serum 
or plasma for laboratory analysis. For example, in glass 
blood collection tubes, the glass interior surface itself 
plays a key role in the activation of blood coagulation  [28] . 
Recent use of plastic, as the principal material of collec-
tion tubes, has required the addition of silica particles or 
other clot activators for optimal formation of serum. These 
particles may be coated with compounds, such as polyvi-
nylpyrrolidone (PVP), to assist the adherence of the par-
ticles to tube walls and facilitate the rapid dispersion of 
silica into the blood specimen. The interior surface of blood 
collection tubes is also usually coated with a surfactant 
to minimize the adherence of blood cells to the tube, 
which reduces hemolysis and better distributes the clot 
activator (e.g., silica) along the tube wall. Without a sur-
factant, the hemolysis of red blood cells after incomplete 
separation from serum will alter the serum composition 
over time. Stoppers of tubes also require a coating with a 
lubricant to improve their ease of removal and to maintain 
the vacuum. Separator gels are also a common compo-
nent of blood collection tubes, and they serve as a barrier 
between serum and clot or plasma and cells, respectively, 
after centrifugation of tubes. A well-recognized drawback 
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of serum/plasma separator tubes is the potential for the 
separator gel to absorb hydrophobic compounds such as 
some drugs  [29] . Another problem is that the gel itself is 
unstable under extreme temperature conditions and can 
produce an oily film in serum/plasma, which in turn can 
obstruct instrument probes with subsequent downtime. 
 In a previous study that has been performed on the 
Diagnostic Products Corporation Immulite 2000/2500 ana-
lyzer by plastic Becton-Dickinson (BD) blood collection 
tubes  [30] , an interference likely attributable to a tube addi-
tive, Silwet L-720 (also shared by other plastic BD tubes) was 
observed. In response to the immunoassay interference, the 
manufacturer has reformulated the blood collection tubes 
to reduce the amount of tube additives  [31] . 
 Other than increased vigilance when inspecting labo-
ratory results and improving the feedback between the 
clinical laboratory and clinicians, there is not much that 
clinical laboratories can do to readily detect blood col-
lection tube problems. It is impractical for clinical labo-
ratories to repeat a tube evaluation study with each new 
lot of tubes, but laboratories should consider comparing 
results from separate lots of the same tube type to detect 
any lot-to-lot variations when first evaluating a new tube. 
Similarly, it is impractical for tube manufacturers to test 
their tubes on all the various assay platforms, but they 
should ensure consistency in the amount and quality of 
any tube additives throughout the whole manufacturing 
process. Diagnostics companies may also help identify 
future tube problems, by providing detailed information 
not only on the tube type but the commercial source of the 
tubes that they use when determining the reference inter-
val for any new assay. Any reference interval study done 
by diagnostics companies on previously developed assays 
with older tubes that are no longer widely used, such as 
glass tubes, should ideally be repeated with tube types 
that are currently used by their customers. Thus, since 
the quality of patient care depends on the quality of all 
the information that a physician uses in making treatment 
decisions, blood collection tubes should be manufactured 
to an extremely high standard like other medical devices. 
 Lipemia 
 Lipemia is traditionally defined as serum or plasma tur-
bidity caused by increased lipoprotein (especially triglyc-
erides-rich lipoproteins) concentration. The prevalence of 
lipemia is lower than that of other unsuitable specimens 
such as those clotted or hemolyzed, but still appears in 
approximately 1 % of samples. Besides pathophysiological 
conditions, preanalytical laboratory errors account for a 
large proportion of lipemic samples (i.e., improper time 
of sampling after a meal or after intravenous infusion of 
triglycerides-rich emulsions for parenteral nutrition) and, 
as such, can be prevented  [11] . 
 There are several mechanisms causing lipemia inter-
ference in laboratory testing. Lipemia interferes with 
nearly all photometric measurements by light scattering 
and absorption. The extent of interference is related to 
lipoprotein sample size and number of particles. In elec-
trophoretic and chromatographic methods, increased 
proportion of lipoproteins may cause additional peaks 
or background noise. When measuring electrolyte con-
centration by flame photometry and indirect potentiom-
etry, falsely decreased concentrations are observed due to 
reduced volume of sample water phase. After centrifuga-
tion, lipemic samples are not homogenous, which results 
with falsely decreased concentrations of water soluble 
constituents in the upper lipid layer  [32] . 
 Although most of the current laboratory instrumenta-
tions offer automated detection of turbidity degree, some 
laboratories still rely on optical identification. Besides 
being highly subjective and arbitrary, this approach is 
unsuitable when a large number of samples have to be 
inspected  [33] . Analyzers may detect the degree of lipemia 
by measuring sample specter on several wavelengths. 
However, there is a large variability across systems, both in 
wavelengths used, and also in the ways of finally express-
ing results. Some studies have also been published, 
which described falsely elevated lipemic indexes in clear 
samples, due to increased concentration of paraproteins 
or some interfering components (methylene dye). Thus, 
samples with unusually high lipemic indexes should also 
be systematically inspected afterwards. 
 Several protocols of eliminating lipemia prior to 
laboratory testing have been proposed. According to the 
Clinical and Laboratory Standards Institute (CLSI) recom-
mendations, ultracentrifugation should be considered as 
the preferred approach. Since this kind of equipment is 
unavailable in most laboratories due to high costs, high 
speed microcentifuge can however be considered as effi-
cient when lipemia is predominantly due to chilomicrons 
 [34] . Several other methods are also based on the physical 
removal of the lipoprotein layer (extraction with hydro-
phobic solvents or precipitation). Nevertheless, atten-
tion should be taken when assessing the concentration of 
hydrophobic components in these samples because as a 
result of lipoprotein removal, their concentration is then 
falsely decreased in the aqueous phase. 
 There are also several problems that should be con-
sidered when dealing with lipemic samples. There is no 
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adequate simulation protocol for testing lipemia. Most 
laboratories spike samples with triglyceride rich infu-
sions (e.g., Intralipid). It has however been described that 
Intralipid-induced lipemia and native lipemia of the same 
extent (measured by the lipemic index) do not produce 
the same bias on measured results  [35] . The manufac-
turer ’ s recommendations about lipemia interferences are 
not unified, and in most cases describe only the effect 
of added Intralipid solution. Therefore, each laboratory 
should check these recommendations on samples with 
native lipemia and have detailed protocols for identifying, 
eliminating and reporting results from lipemic samples. 
 Adherence to guidelines 
 Medical guidelines are evidence-based and include con-
sensus of best practice in healthcare. Healthcare staff are 
obliged to know relevant medical guidelines and decide 
on their application for individual patients. Adherence to 
guidelines standardizes medical care, raises care quality 
and reduces patient risks. Laboratory results following 
venous blood sample collection and analysis are impor-
tant in the clinical diagnosis and treatment of patients, so 
ordering of analyses as well as blood drawing procedures 
should always adhere to medical guidelines. However, 
venous blood sample collection guidelines are not always 
followed  [36, 37] , and so interventions may be needed to 
reduce patient safety risks. 
 The low preanalytical error rates noted by hospital 
laboratories calls for large databases as well as appropri-
ate techniques for the detection of errors and their conse-
quent reduction. Comparisons of error rates and the effect 
of interventions have therefore not been possible to study 
at individual hospital wards or physicians ’ offices. To be 
able to assess frequent  “ near-misses ” (i.e., mistakes that 
may lead to adverse events) during blood drawing would 
allow for comparison to guidelines, benchmarking of pre-
analytical practices between wards and physicians ’ offices 
and to follow the effect of corrective educational inter-
ventions than the current assessment of underreported 
incidents or registered rare adverse events. We therefore 
developed and validated a self-reported questionnaire to 
assess frequently occurring, error-prone everyday blood 
drawing tasks at the hospital ward/physicians ’ office 
level  [38] . To reflect varying preanalytical conditions at 
this healthcare level, we also used the high frequency of 
low-level hemolyzed venous blood serum samples instead 
of the low frequency of high-level hemolyzed samples, 
which is commonly used for rejection of specimens to 
avoid analytical interference  [39] . To assess primary 
healthcare physicians ordering of analyses we compared 
the ordering frequency of analyses to medical guidelines 
for a number of diseases. 
 The venous blood sample collection questionnaire 
surveys showed, e.g., that hospital ward staff devi-
ated from guidelines as 20 % stated that they sometimes 
labeled test tubes after sampling away from the patient 
and 10 % did not always compare patient identification 
with the test request. Of physicians ’ office blood drawing 
staff, only 54 % always performed patient identification 
according to guidelines, 6 % stated they always allow 
patients to rest the recommended time prior to sampling, 
and 12 % to release venous stasis as soon as possible 
during sampling. Samples collected in the physician ’ s 
office with the highest prevalence of (low-grade) hemoly-
sis were 6.1 times (95 % CI 4.0 – 9.2) more often hemolyzed 
as compared with the physician ’ s office with the lowest 
prevalence. Rural physician ’ s office serum samples were 
hemolyzed 1.7 times more often compared to the urban 
physicians ’ office samples  [39] . The national diabetes 
guidelines regarding the frequency of glycated albumin 
and urinary albumin analysis ordering were followed by 
physicians in 12 and 10 physicians ’ office out of 32 in the 
County Council, respectively. 
 Repeated questionnaire surveys and monitoring of 
sample low-level hemolysis of hospital ward and physi-
cians ’ offices staff practices would highlight specific prob-
lems and make it possible to follow the effect of correc-
tive actions. We performed a large-scale short educational 
intervention on all (approx. 2500) County Council staff, 
but venous blood sample collection handling practices 
were not improved (low-level sample hemolysis remained 
unchanged)  [40] , whereas patient identification, test tube 
labeling and information search procedures improved 
(questionnaire survey  – manuscript) when comparing 11 
physicians ’ offices before and after intervention. 
 Given the instruments to assess the frequent preana-
lytical  “ near-misses ” at all healthcare levels, the chal-
lenge to the laboratory medicine profession is now to 
join in finding effective educational methods to increase 
healthcare staff adherence to medical guidelines. 
 Preanalytical requirements 
of urinalysis 
 Sediment analysis has been the gold standard in urinaly-
sis, whereas automation (i.e., automated microscopy, flow 
cytometry) has improved accuracy. Since urine samples 
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are collected by patients, urinalysis is highly susceptible 
to preanalytical problems, and focusing on these issues 
is essential to improve reliability of testing since preana-
lytical demands will be stricter as a test tends to provide 
more reliable results. Informing patients involves more 
than only explaining the practical aspects of sampling, 
as the influence of biological factors (e.g., exercising, 
contamination) should be particularly stressed. Illus-
trated instructions can be provided, while procedures 
should take into account patient characteristics, e.g., the 
presence of a catheter. Midstream (clean-catch) portions 
of first morning urine samples collected in a sterile con-
tainer are recommended. Overnight bacterial growth in 
the bladder is possible, and bacteriuria can influence the 
formed elements. Higher reproducibility is achieved by 
using second morning urine. Red blood cell morphology 
remains a separate analysis; correct assessment depends 
on pH and osmolality. Washing the intimate parts mini-
mizes contamination, but the use of soap or antiseptics is 
dissuaded due to its influence on germs  [41] . 
 Container design should enable easy sampling and 
ensure optimal transport. Requirements can be added in 
the function of procedures (e.g., amber-colored containers 
for light sensitive analytes). Besides the use of a primary 
container, it is advised to aliquot the original sample 
for chemical, microbiology and morphology analyses. 
Vacuum systems allow sample aspiration into secondary 
containers, but can only be used for chemical analysis, 
since the pressure difference during aspiration causes 
disintegration of casts. In low conductivity samples, red 
blood cell count is lower in vacuum tubes. Although it is 
not good practice, there can be a tendency to dip strips in 
the container. It is recommended to transfer urine to the 
strip instead of immersing the strip into the sample  [41] . 
 Increased time lag between sampling and analysis, lack 
of temperature control and use of non-preserved samples 
not analyzed within 2 h can decrease sample quality. 
Alkaline pH, low density and low osmolality promote 
lysis. Stabilizers prevent metabolic changes and bacte-
rial growth. Ethanol and polyethylene glycol are used to 
preserve cells. Containers prefilled with boric acid, formic 
acid or other stabilizers are also used  [42] . Red blood cells 
are difficult to stabilize, in contrast to white blood cells, 
casts and epithelial cells. Adding formaldehyde results in 
bad preservation of red blood cells. Preservatives can also 
inhibit protein degradation. The 24 h collection represents 
the reference method for stable analyte quantification 
(protein:creatinine ratio is an alternative). No preservatives 
are necessary if strip testing is performed within 24 h and 
the sample is refrigerated. However, when refrigeration is 
unfeasible, preservatives can thus be added, the choice 
of which depends on the analyses, since some enzymatic 
reactions may be negatively affected. Boric acid keeps the 
pH acid, but may affect strip reactions; its addition impairs 
correct pH measurements. Preservative containing tubes 
preserve strip results for 6 – 24 h (exceptions are glucose and 
nitrite). Particles should be examined within 1 h (at room 
temperature) or 4 h (refrigerated), to prevent lysis. Refrig-
eration causes precipitation of urates and phosphates. Par-
ticle lysis is pronounced with higher pH and lower density. 
Long standing samples show a pH increase.  Proteus sp . 
produce urease, resulting in an increase of pH. Undissolved 
powder causes a background signal in flow cytometric red 
blood cell counting. There is no preservative that can be 
used to stabilize urine for strip and particle analysis  [41] . 
 Preanalytical phase for molecular 
biology testing 
 Molecular biology testing and proteomic techniques are 
rapidly evolving methods in clinical laboratories and 
could move the diagnostic procedures on a higher level 
than classical methods. As other fields of IVDs, the high 
diagnostic potential must be accompanied by higher 
quality assurance. Analytical technologies for molecular 
biology and proteomic analysis are on very high level, but 
the preanalytical phase is still not clear enough, nor speci-
fied. The biggest problem is the high degree of heterogene-
ity of methods as well as samples used. 
 As regards DNA, formalin-fixed paraffin-embedded 
samples may be stored for years, since both DNA and RNA 
are fairly stable. The pre-fixing steps are established for 
many years and are not likely to be changed. The biggest 
problem is the extraction of nucleic acids, as they are 
often degraded, cross-linked to proteins and modified. 
Automated extraction is available and should henceforth 
be preferred  [43] . Extracted material is usually well-suited 
for polymerase chain reaction (PCR), sequencing faces to 
DNA breaks and other DNA modifications  [44] . 
 As regards amniotic fluid and chorionic villus, the 
samples should be handled very carefully as they are 
usually irreplaceable. Contamination of amniotic fluid by 
maternal sources could be decreased by the cultivation 
of amniotic fluid cells, but it does not help in chorionic 
villus samples. Standard procedures, published by Ameri-
can College of Medical Genetic must be followed (e.g., in a 
recent survey of 35 laboratories in the US, 60 % tested the 
appearance of maternal cells, only)  [45] . 
 The assessment of free DNA and/or RNA in plasma 
is increasingly used in laboratory diagnostics and is 
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probably one of the most appealing perspective areas 
in molecular biology testing. The differences between 
plasma and serum are substantial, plasma being consid-
ered the most suited material. The concentration of DNA 
in serum is usually higher due to the release of cell-free 
DNA from leukocytes during clotting, which has implica-
tions mostly in testing cell-free DNA in cancer, trauma and 
transplant patients  [46] . Fetal DNA in maternal plasma is 
considered to have the same concentration as in mater-
nal serum. Careful centrifugation, followed by the addi-
tional step of microcentrifugation or filtration is effective 
in producing cell-free plasma. Extraction by phenol-chlo-
roform-isoamylalcohol seems to be preferable. However, 
the stability of sample differs and for short-term storage 
(i.e., up to 8 h) EDTA plasma may be used, but for longer 
storage the use of special sample tubes (e.g., PAX gene ™ ) 
is advisable. The typical concentration of free DNA in 
plasma in healthy persons varies from 0 to 100 mg/mL 
of blood (on average 30 ng/mL), the vast majority being 
as double-stranded DNA. Although the clearance mech-
anisms have not been fully elucidated, free fetal DNA in 
maternal blood is cleared rapidly after birth, with an usual 
half-life of approximately 16 min. 
 MicroRNA are also receiving growing interest. At vari-
ance with DNA, its plasma concentration is higher than in 
serum, but the removal of cellular and subcellular com-
ponents is effective to reduce the plasma concentration to 
values similar to the serum. MicroRNA are stable at room 
temperature for up to 24 h, refrigerated or frozen for up 
to 72 h. Hemolysis has different influence on different 
microRNA, with the concentration of some of them being 
increased in hemolyzed specimens. 
 The peptidome analysis of human urine is challenging, 
since urine has many potential variables, including sam-
pling, storage, freezing conditions, freeze/thaw cycles pH, 
urine salt and proteins, blood and bacterial presence. Sep-
aration of proteins by magnetic beads, followed by MALDI-
TOF mass spectrometry is henceforth recommended. 
 In conclusion, no consensus has been reached so far 
on the best preanalytical practices in the field of molecular 
biology and standardization of all preanalytical activities 
in molecular biology and proteomic analyses is thereby 
deeply advisable and needed. 
 Preanalytical phase for hemostasis 
and platelet function testing 
 A number of preanalytical variables have been shown to 
affect the results of many laboratory tests including those 
related to hemostasis and thrombosis  [28, 47 – 51] . One 
important preanalytical variable affecting some clotting 
tests as well as platelets is hemolysis  [52] . Some coagula-
tion analyzers are already available with automated pre-
analytical checks. The CS2100i (Sysmex Corporation), e.g., 
has novel features related to processing samples which 
contain interfering substances including hemoglobin. 
For all clotting endpoints transmitted light is monitored 
at five different wavelengths (340, 405, 575, 660 and 880 
nm). The instrument automatically checks test plasma for 
the presence of hemolysis (as well as icterus and lipemia) 
and flags results to alert the operator. We decided to inves-
tigate the effect of hemolysis on routine coagulation tests. 
Samples with visible hemolysis that failed the empirical 
acceptance criteria were retained (n = 59), and analyzed 
alongside matched samples from the same patients which 
were free of interference and had been collected within 
4 h of the former. We measured free hemoglobin in the 
sample with hemolysis, which ranged from 0.5 to 9.0 g/L 
(mean 1.7 g/L). In relation to some individual cases, the 
differences were sufficient to influence patient manage-
ment. For example, in four samples where the baseline 
D-dimer result was below the cut-off for venous thrombo-
embolism, D-dimer was found to be falsely elevated above 
the diagnostic threshold in those with visible hemolysis, 
which could lead to further and unnecessary examina-
tions depending on the probability scoring. Five activated 
partial thromboplastin times (APTTs) with one reagent 
were more than 4 s different between clear and hemolyzed 
samples, with changes in both directions. False normal 
APTTs were obtained in hemolyzed samples from two 
patients when analyzed with a second APTT reagent. 
 Under-filling of citrated blood samples is another crit-
ical preanalytical variable, which can affect the results of 
several  – if not all  – clotting tests. It has been reported that 
for 5 mL siliconized glass tubes (Vacutainer, Becton Dick-
inson) there is no difference between the results obtained 
from 100 % full tubes and 60 % full tubes for Prothrombin 
Time (PT) and 70 % full for APTT  [53] . Identical results 
were reproduced in further studies  [54] . It is likely that the 
effects of under-filling may depend on the blood collec-
tion tube used, including composition, inner dimensions 
and the air space to surface area ratio. Under-filled 3 mL 
plastic tubes (Vacutainer Plus, Becton Dickinson) which 
failed the local acceptance criteria (i.e., containing  < 80 % 
of target volume) were retained (n = 18) and analyzed 
with a Sysmex CS2100 alongside matched samples from 
the same patients which contained 95 % – 100 % of target 
fill volume and were collected within 4 h of the former. 
All samples had normal hematocrit values. Under-filling 
ranged from 56 % to 79 % (mean, 67 % ). The results of 
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screening tests (PT, APTT, thrombin time) were signifi-
cantly longer when tubes were under-filled, frequently 
to the extent that patient management decisions could 
be affected. Fibrinogen was significantly lower in under-
filled samples. Therefore, blood samples from subjects 
with normal hematocrit values collected into these 3 mL 
tubes should not be accepted for analysis if  < 80 % full. 
 Platelet function testing by optical aggregometry 
has proved difficult to standardize and one reason is 
the important influence of preanalytical variables. Some 
guidance is available in relation to this  [55] , which recom-
mends the following: collect samples after fasting and 
resting; use 19 – 21 g needle (butterfly cannulae allowed if 
blood flow is not restricted); do not use the first 3 – 5 mL 
collected for platelet function testing; use evacuated or 
syringe collection; utilize 105 – 109 mM trisodium citrate 
(preferable buffered to help maintain pH); maintain at 
room temperature; do not transport via pneumatic tube 
system; keep interval between collection and analysis 
preferably between 30 and 120 min, but  < 4  h. Platelets 
responses to agonists are labile following collection, so 
we investigated platelet responses to standard agonists in 
platelet rich plasma (PRP) from five normal subjects pre-
pared from whole blood that had been stored for up to 5 h. 
The mean maximum aggregation responses are shown in 
the Table  1 , and it can be seen that important deteriora-
tion in responses were beginning after 3 h storage. We 
conclude that for these reagents testing should be per-
formed within 2 h of sample collection. 
 Auditing of the preanalytical 
phase  – ISO assessors 
 Several medical laboratories in Europe are accred-
ited according to the ISO15189 standard, although the 
Agonist Time interval, h
 < 0.5 1 2 3 4 5
Mean maximum aggregation,  % 
Ristocetin (1.25 mg/mL) 80 78 77 68 58 50
ADP (3.0  μ mol/L) 58 78 80 70 57 49
Collagen (1.0  μ g/mL) 44 45 41 36 26 18
Arachadonic acid (1.5 mmol/L) 92 92 92 84 69 26
 Table 1   Platelet responses to standard agonists in platelet rich 
plasma (PRP) form five normal subjects prepared form whole blood 
that had been stored for up to 5 h. 
percentage of accredited laboratories varies widely among 
countries, with frequency ranging from 0 % to 75 %  [56] . 
There is an ongoing debate on the best way to harmonize 
this process, but there are also concerns regarding how 
thoughtfully the preanalytical phase would be covered by 
the accreditation process. Important issues include, e.g., 
appropriate test requisition, patient preparation, phlebot-
omy performed outside the laboratory (perhaps by a differ-
ent staff), sample stability and handling of other sample 
materials such as saliva, cerebrospinal fluid or sampling 
from catheters  [11] . The issues are complex and wide-
spread, and often the accreditation process tends to focus 
on the capability of the laboratory production itself. Of 
note, preanalytical errors will of course still be  prevalent 
in an accredited laboratory  [57] , although the substan-
tial decrease in the number of significant non-conform-
ities was observed in accredited laboratories over time, 
suggesting that ISO15189 does contribute to the quality 
improvement of accredited laboratories  [58] . Moreover, 
even though a variety of preanalytical issues are actually 
covered in the ISO15189, it is often challenging to address 
the same topics as an ISO assessor along with all the other 
important aspects in the accreditation procedure. 
 Auditing of the preanalytical 
phase  – practical overview 
 Due to the complexity of the preanalytical phase it has not 
been possible to standardize preanalytical processes to 
the same extent as those of the analytical phase, despite 
its importance for sample quality, and hence laboratory 
efficiency, or patient or healthcare worker safety  [59] . To 
investigate preanalytical procedures and practices with a 
consistent method for all blood collection systems, stand-
ardized data collection forms were used to enable audit-
ing of the preanalytical practices in hospitals in different 
countries. The processes of blood collection were assessed 
from storage of the blood collection materials throughout 
blood specimen collection itself, transport and process-
ing of the samples within the laboratory and the resulting 
sample quality. By following the blood samples through 
the complete process, it was possible to link specific pre-
analytical attributes to sample quality deficiencies. Obser-
vation of the processes on the ward also allows assess-
ment of behavior, which is important for the safety of 
healthcare workers. 
 The preanalytical phase has been observed for 3597 
blood collection tubes over 1350 blood collection proce-
dures. Sample quality was assessed for 8016 chemistry 
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and 3532 coagulation tubes. For all clinical chemistry 
samples, 8.9 % showed some level of hemolysis. For 
the hemolyzed samples where the preanalytical phase 
had been observed, 47 % had prolonged use of tourni-
quet, 31 % were drawn through catheters and for 38 % 
the disinfectant was not allowed to dry before veni-
puncture, three possible causes of hemolysis  [60] . For 
serum clinical chemistry samples, 5.9 % showed fibrin 
formation postcentrifugation. Where fibrin formation 
was observed in serum samples, 26 % had less than the 
manufacturers recommended clotting time and 81 % 
had not been mixed impacting the suspension of the 
clot activator. Additional observations were; includ-
ing incorrect identification procedure of the patient 
(56 % ), tubes labeled prior to collection (61 % ), coagula-
tion tubes filled to  < 90 % of nominal tube volume (7 % ), 
which has the potential to lead to incorrect analytical 
results  [53] . Gloves were not worn in 37 % blood collec-
tion procedures, and the activation of the needle safety 
device was incorrect in 19 % . In conclusion there are 
still considerable improvements that can be made in 
order to improve processes and practices that are key 
to sample quality, and hence laboratory efficiency, or 
patient or healthcare worker safety. Accordingly, stand-
ardized audit methodology enables an institution to 
compare results between different areas of the hospi-
tal in order to understand how different practices are 
impacting sample quality. The prospective nature of 
the audits permits identification of issues within an 
institution based on more data than that from rejected 
samples and therefore affords a more complete under-
standing for all of those involved in the preanalytical 
phase. The results can be used in a targeted manner 
for information and training purposes, providing the 
direct link between the blood collection practice and 
the resulting sample quality issues. 
 External Quality Assessment 
for the preanalytical phase 
 According to the ISO 15189 5.6.4, External Quality Assess-
ment (EQA) programs should, as far as possible, provide 
clinically relevant challenges that mimic patient samples 
and have the effect of checking the entire examination 
process, including pre- and postexamination procedures 
 [61] . Although a lot of focus has been given to the prean-
alytical phase, claiming that it accounts for most of the 
laboratory errors, few initiatives have been taken to incor-
porate this into regular EQA. One of the reasons for this is 
probably that the examination of preanalytical errors are 
best done in local settings in specially designed studies. 
When it is incorporated into EQAs, it is usually done by 
circulating questionnaires or asking participants to reg-
ister onto a web site to report their practices and errors 
 [62] . Sometimes samples addressing preanalytical prob-
lems (e.g., hemolysis or lipemia) are incorporated in tra-
ditional EQAs, or else specific samples containing defined 
amounts of interfering substances may be prepared and, 
with results further assessed for comparability and bias 
across distant laboratories, even using rather different 
equipment  [63, 64] . 
 Cases reports: the preanalytical 
detective 
 The preanalytical phase is a complex and dynamic 
process differing not just from one hospital environment 
to the next, but within the hospital as well. Preanalytical 
errors often cause random errors undetectable by normal 
quality control methods. In order to determine the cause 
of these random errors, it is necessary for the laboratory 
professional to become a sort of  “ detective ” . Through a 
series of deductions and research, (s)he can identify 
the cause and put corrective actions in place, whenever 
possible. 
 A number of case studies illustrate this approach, 
e.g., why fibrin masses were created in serum samples 
after overnight shipment, which led to samples requir-
ing additional processing steps ? What caused elevated 
potassium results, which led to a patient being admit-
ted as an emergency but whose potassium normalized 
upon admission ? In this latter case there were several 
incidents, where the potassium analysis of the origi-
nal specimen was confirmed by repeat analysis on an 
additional tube collected at the same time. Results were 
also confirmed and reproduced on another analyzer. 
There was no visible hemolysis or procedures that were 
likely to lead to hemolysis. In another case patients were 
admitted for bypass surgery and had postoperative com-
plications. Although, their preoperative potassium was 
within the normal range, the postoperative concentra-
tion had risen to  > 7.0  mmol/L. This led the laboratory 
professional to question whether this was a collection or 
rather a laboratory error  [65] . Finally, why do high levels 
of proteins (e.g.,  > 135 g/L) cause sporadic inappropriate 
separation of plasma and serum from cells in gel separa-
tion tubes  [66] ? 
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 In all of these cases, procedures and patient treatment 
regimes normally outside the control of the laboratory 
led to preanalytical errors that have impacted on sample 
quality, laboratory efficiency and patient care. Recom-
mendations should hence be issued and followed to 
support strategies and practical policies that laboratories 
can implement, to reduce the impact of the preanalytical 
errors, and thereby increase laboratory efficiencies and 
reduce the potential for inappropriate patient care  [67] . 
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